Regeneron Pharmaceuticals Outlines 2026 Growth Catalysts and Strong Q2 Performance

Regeneron Pharmaceuticals (NASDAQ: REGN) executives, during a Wells Fargo investor conference, detailed plans for continued growth, upcoming regulatory milestones, and pipeline programs. The company reported double-digit top- and bottom-line growth in Q2, with EYLEA HD, DUPIXENT, and LIBTAYO achieving all-time quarterly sales highs. Regeneron also completed repayment of its Sanofi development balance, allowing it to record its full share of DUPIXENT and KEVZARA profits. Key pipeline catalysts for 2026 include a November PDUFA date for cemdisiran monotherapy in generalized myasthenia gravis and pivotal data for pozelimab plus cemdisiran in paroxysmal nocturnal hemoglobinuria.